Foundation for Mitochondrial Medicine

AA

A A
Foundation for Mitochondrial Medicine

Clinical Trials

The Importance of Supporting Clinical Research Into Mitochondrial Dysfunction

Nearly every major disease that affects humans as we age may have part of its genesis in mitochondrial dysfunction. Even though scientists have known about mitochondria since before 1900, the area of mitochondrial medicine is still relatively new. The discoveries of most mitochondrial diseases have occurred within the last 30 years.

Because the field of mitochondrial medicine is relatively new, drug development for mitochondrial disease has really only just begun. The road to successful new drugs and drug therapies is long and expensive — on average, it takes 13 years and $1 billion to bring a drug to market. There are many failures along the way, with about 90% of new drugs failing in early phases of clinical trial development.

The Foundation for Mitochondrial Medicine is focused on treatments and funding the cures. We are optimistic for future innovative technologies and discoveries to correct or work around mitochondrial dysfunction. Financial support for FMM means momentum to accelerate entry into clinical trials which will in turn propel research faster toward the cures.

A clinical trial for individuals with primary mitochondrial myopathy is now enrolling participants. If you are interested in participating in a clinical trial and would like more information, visit the clinicaltrials.gov and mitotrials.com websites and see information below to learn more. Additional questions, email info@mitochondrialdiseases.org.

Clinical trial for individuals with primary mitochondrial myopathy (click tabs below to expand)

MMPOWER-3 Trial Sites
Primary Mitochondrial Myopathy Community Webinar Summary
Resources
  • Stealth BioTherapeutics website: mitotrials.com
  • Clincaltrials.gov:  When searching in clinicaltrials.gov with search word elamipretide, the MMPower study is the 5th study down the page: A Trial to Evaluate the Safety and Efficacy of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Extension (MMPOWER-3).

Stay Connected with FMM

  • This field is for validation purposes and should be left unchanged.
Translate »